Skip to content

Drug interactions

Everolimus + Mobocertinib

Severity: Moderate

Everolimus and Mobocertinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Mobocertinib is a moderate CYP3A inducer and may reduce everolimus levels, potentially compromising efficacy. Mobocertinib also carries QT-prolonging risk, which is not shared by everolimus.

What this interaction means in plain words

Everolimus and Mobocertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Evidence level: Low

Why it happens

Mobocertinib induces CYP3A4, increasing everolimus metabolism.

What to do

Monitor everolimus trough concentrations and clinical response, and increase the everolimus dose if levels are subtherapeutic. Prefer an alternative if one is available.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Everolimus and Mobocertinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Everolimus with Mobocertinib?

MediHelp rates the interaction as moderate. Everolimus and Mobocertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Mobocertinib is a moderate CYP3A inducer and may reduce everolimus levels, potentially compromising efficacy. Mobocertinib also carries QT-prolonging risk, which is not shared by everolimus.

How serious is the interaction between Everolimus and Mobocertinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor everolimus trough concentrations and clinical response, and increase the everolimus dose if levels are subtherapeutic. Prefer an alternative if one is available.

What other medicines interact with Everolimus?

MediHelp also lists interactions of Everolimus with, for example, Bcg vaccine live, Influenza virus vaccine quadrivalent intranasal, Levoketoconazole. The full list is on the Everolimus page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in